Luteolin suppresses neuroinflammation by modulating microglial activation and antioxidant defenses
This systematic review synthesizes preclinical evidence on the role of luteolin in neuroinflammation associated with central nervous system disorders. The review focuses on luteolin's mechanisms of action, including suppression of aberrant microglial activation, modulation of pro-inflammatory signaling pathways, and enhancement of endogenous antioxidant defenses. The direction of effect is reported as beneficial, though no pooled effect sizes or quantitative data are provided.
The authors note significant limitations, including luteolin's limited oral bioavailability and restricted blood-brain barrier permeability, which may hinder clinical translation. The review does not report on study populations, sample sizes, comparators, or specific outcomes, and safety data are absent.
Given the preclinical nature of the evidence and the pharmacokinetic challenges, the findings should be interpreted cautiously. Further research is needed to determine whether luteolin can be effectively delivered to the central nervous system and whether these anti-inflammatory effects translate to clinical benefit in humans.